TherapeuticsMD Q2 license revenue falls; continues to evaluate strategic alternatives

TherapeuticsMD

11/08/2026 21:09

Overview
US pharmaceutical royalty company's Q2 license revenue declined yr/yr due to lower licensed product sales
Net income from continuing operations fell compared to prior yr
Company continues to evaluate strategic alternatives, including possible merger or asset sale

Outlook
Company will recognize a CAD 500,000 milestone payment as revenue in Q3 2026
TherapeuticsMD continues to evaluate strategic alternatives, including possible mergers or asset sales
No assurance or timetable for completion of strategic review has been established

Result Drivers
LICENSED PRODUCT SALES - Co said lower sales of licensed products drove decline in Q2 license revenue

Company press release: ID:nBwb4msZ3a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income from Cont Ops
 
$164,000
 
Q2 Operating Expenses
 
$1.69 mln
 

Reuters Recommended Reads
Aug 11 - Xtant Medical Q2 revenue falls on asset sales and lost license revenue
Aug 10 - Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
Aug 11 - LB Pharmaceuticals Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)